AMN Healthcare Services (NYSE:AMN), the nation’s largest healthcare staffing firm, saw its shares jump on Thursday after providing a blockbuster revenue outlook for the first quarter of 2026.
AbbVie (NYSE:ABBV) announced on February 20, 2026, that the U.S. Food and Drug Administration (FDA), has approved the combination of VENCLEXTA (venetoclax) and acalabrutinib for adult patients with previously untreated chronic lymphocytic leukemia (CLL).
Madrigal Pharmaceuticals (NASDAQ:MDGL), the West Conshohocken, Pennsylvania-based leader in liver disease therapies, reported fourth-quarter revenue that outpaced Wall Street estimates, driven by the explosive commercial trajectory of its flagship MASH treatment, Rezdiffra.
Plano, Texas-based Integer Holdings (NYSE:ITGR), a leading outsource manufacturer of medical devices and components, reported fourth-quarter net income of $48.6 million, or $1.38 per share, for the period ended December 2025.
Hims & Hers Health (NYSE:HIMS), the San Francisco-based telehealth leader, announced a definitive agreement on Thursday to acquire Eucalyptus, an Australian digital health powerhouse, in a deal valued at up to $1.15 billion.
Pediatrix Medical Group (NYSE:MD) reported fourth-quarter results that matched its recently raised internal projections, as the company’s multi-year restructuring begins to yield a more predictable, hospital-centric financial profile.
Merck (NYSE:MRK) released new data today demonstrating that its recently approved monoclonal antibody, Enflonsia (clesrovimab), remains safe and effective for high-risk children entering their second respiratory syncytial virus (RSV) season.
Materialise (NASDAQ:MTLS) reported fourth-quarter financial results that showcased the growing dominance of its healthcare division, helping the company achieve a significant jump in profitability despite a mixed macroeconomic backdrop.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo moved a step closer to expanding the use of their blockbuster cancer therapy, Enhertu, into the curative-intent setting for early-stage breast cancer.
Eli Lilly and Company (NYSE:LLY) today announced positive topline results from its Phase 3b TOGETHER-PsO trial, demonstrating that treating psoriasis and obesity simultaneously yields significantly better outcomes than addressing skin disease alone.
Insulet (NASDAQ:PODD), the Acton, Massachusetts-based maker of the Omnipod insulin delivery systems, reported stronger-than-expected fourth-quarter 2025 results.
Bausch + Lomb (NYSE:BLCO) reported fourth-quarter revenue that surpassed Wall Street expectations, showcasing strong top-line momentum even as the global eye health company posted a net loss for the period.
